The introduction of new vial sizes for PROLASTIN by Grifols is likely to enhance the company's product offering and could lead to increased usage and sales. This development is significant as PROLASTIN is the most prescribed therapy worldwide for alpha1-antitrypsin deficiency, a condition that leads to severe lung disease. The expansion of product options demonstrates Grifols' commitment to addressing this medical need and could positively impact the company's financial performance and investor sentiment in the short term.